{"id": "article-17708_0", "title": "Antiplatelet Medications -- Continuing Education Activity", "content": "Over time, numerous antiplatelet agents have been developed with a multitude of indications. Antiplatelet medications divide into oral and parenteral agents, and oral agents subdivide further based on the mechanism of action. Aspirin was the first antiplatelet medication and is a cyclooxygenase inhibitor. Other oral antiplatelet include clopidogrel, ticagrelor, and prasugrel, cilostazol, and dipyridamole. Glycoprotein IIb/IIIa inhibitors such as tirofiban and eptifibatide are only available as parenteral agents and are used in acute phases of acute coronary syndrome. This activity reviews the indications, contraindications, action, adverse events, and other key elements of antiplatelet drugs essential to clinical practice.", "contents": "Antiplatelet Medications -- Continuing Education Activity. Over time, numerous antiplatelet agents have been developed with a multitude of indications. Antiplatelet medications divide into oral and parenteral agents, and oral agents subdivide further based on the mechanism of action. Aspirin was the first antiplatelet medication and is a cyclooxygenase inhibitor. Other oral antiplatelet include clopidogrel, ticagrelor, and prasugrel, cilostazol, and dipyridamole. Glycoprotein IIb/IIIa inhibitors such as tirofiban and eptifibatide are only available as parenteral agents and are used in acute phases of acute coronary syndrome. This activity reviews the indications, contraindications, action, adverse events, and other key elements of antiplatelet drugs essential to clinical practice."}
{"id": "article-17708_1", "title": "Antiplatelet Medications -- Continuing Education Activity", "content": "Objectives: Summarize the mechanisms of action of the different antiplatelet agents. Identify the appropriate indications for the various antiplatelet drugs. Describe the potential adverse event profiles of the different antiplatelet agents. Review interprofessional team strategies for improving care coordination and communication to enhance patient outcomes and minimize adverse events with antiplatelet medications. Access free multiple choice questions on this topic.", "contents": "Antiplatelet Medications -- Continuing Education Activity. Objectives: Summarize the mechanisms of action of the different antiplatelet agents. Identify the appropriate indications for the various antiplatelet drugs. Describe the potential adverse event profiles of the different antiplatelet agents. Review interprofessional team strategies for improving care coordination and communication to enhance patient outcomes and minimize adverse events with antiplatelet medications. Access free multiple choice questions on this topic."}
{"id": "article-17708_2", "title": "Antiplatelet Medications -- Indications", "content": "Antiplatelet\u00a0medications divide into oral and parenteral agents. Oral agents subdivide further based on the mechanism of action. Aspirin was the first antiplatelet medication and is a cyclooxygenase inhibitor. Other oral antiplatelet agents include clopidogrel, ticagrelor, prasugrel, pentoxifylline, cilostazol, and dipyridamole. Glycoprotein IIb/IIIa inhibitors such as tirofiban and eptifibatide are only available as parenteral agents and are used in acute coronary syndrome (ACS). [1] The following\u00a0is a list of indications of antiplatelet medications:", "contents": "Antiplatelet Medications -- Indications. Antiplatelet\u00a0medications divide into oral and parenteral agents. Oral agents subdivide further based on the mechanism of action. Aspirin was the first antiplatelet medication and is a cyclooxygenase inhibitor. Other oral antiplatelet agents include clopidogrel, ticagrelor, prasugrel, pentoxifylline, cilostazol, and dipyridamole. Glycoprotein IIb/IIIa inhibitors such as tirofiban and eptifibatide are only available as parenteral agents and are used in acute coronary syndrome (ACS). [1] The following\u00a0is a list of indications of antiplatelet medications:"}
{"id": "article-17708_3", "title": "Antiplatelet Medications -- Indications", "content": "Acute coronary syndrome Post percutaneous coronary intervention (PCI) with stenting Mechanical heart valves in combination with warfarin Acute ischemic stroke Post percutaneous intervention of peripheral arterial disease Device closure of an atrial septal defect (ASD) for at least six months Stable angina Post-coronary\u00a0artery bypass grafting surgery Essential thrombocytosis Primary prevention of coronary artery disease Prevention of colon cancer Kawasaki disease Acute rheumatic disease Post patent ductus arteriosus (PDA) device closure for the first six months Acute pericarditis Atrial fibrillation with a high risk of stroke Primary prevention of venous thromboembolism", "contents": "Antiplatelet Medications -- Indications. Acute coronary syndrome Post percutaneous coronary intervention (PCI) with stenting Mechanical heart valves in combination with warfarin Acute ischemic stroke Post percutaneous intervention of peripheral arterial disease Device closure of an atrial septal defect (ASD) for at least six months Stable angina Post-coronary\u00a0artery bypass grafting surgery Essential thrombocytosis Primary prevention of coronary artery disease Prevention of colon cancer Kawasaki disease Acute rheumatic disease Post patent ductus arteriosus (PDA) device closure for the first six months Acute pericarditis Atrial fibrillation with a high risk of stroke Primary prevention of venous thromboembolism"}
{"id": "article-17708_4", "title": "Antiplatelet Medications -- Mechanism of Action", "content": "Antiplatelets can be classified based on the mechanism of action as follows [2] [3] : Platelet aggregation inhibitors such as; Aspirin and related cyclooxygenase inhibitors Oral\u00a0thienopyridines such as clopidogrel, ticagrelor, and prasugrel Glycoprotein platelet inhibitors (e.g., abciximab, eptifibatide, tirofiban) Protease-activated receptor-1 antagonists (e.g., vorapaxar) Miscellaneous (e.g., dipyridamole - a nucleoside transport inhibitor and phosphodiesterase type 3 (PDE3) inhibitor,\u00a0cilostazol - also a PDE3 inhibitor)", "contents": "Antiplatelet Medications -- Mechanism of Action. Antiplatelets can be classified based on the mechanism of action as follows [2] [3] : Platelet aggregation inhibitors such as; Aspirin and related cyclooxygenase inhibitors Oral\u00a0thienopyridines such as clopidogrel, ticagrelor, and prasugrel Glycoprotein platelet inhibitors (e.g., abciximab, eptifibatide, tirofiban) Protease-activated receptor-1 antagonists (e.g., vorapaxar) Miscellaneous (e.g., dipyridamole - a nucleoside transport inhibitor and phosphodiesterase type 3 (PDE3) inhibitor,\u00a0cilostazol - also a PDE3 inhibitor)"}
{"id": "article-17708_5", "title": "Antiplatelet Medications -- Mechanism of Action", "content": "Aspirin is the most commonly used oral antiplatelet drug. It works by irreversibly inhibiting the cyclooxygenase enzyme (COX) activity in the prostaglandin synthesis pathway (PGH2). This prostaglandin is a precursor of thromboxane A2 (TXA2) and PGI2.\u00a0Thromboxane A2 works by inducing platelet aggregation and vasoconstriction, and COX-1 mediates its production, while PGI2 works by inhibiting platelet aggregation and induces vasodilation, and is mediated by COX-2. Low-dose\u00a0aspirin (75 mg\u00a0to 150 mg) can induce complete or near-complete inhibition of COX-1, thus inhibiting the production of TXA2, while larger doses are required to inhibit COX-2. [4]", "contents": "Antiplatelet Medications -- Mechanism of Action. Aspirin is the most commonly used oral antiplatelet drug. It works by irreversibly inhibiting the cyclooxygenase enzyme (COX) activity in the prostaglandin synthesis pathway (PGH2). This prostaglandin is a precursor of thromboxane A2 (TXA2) and PGI2.\u00a0Thromboxane A2 works by inducing platelet aggregation and vasoconstriction, and COX-1 mediates its production, while PGI2 works by inhibiting platelet aggregation and induces vasodilation, and is mediated by COX-2. Low-dose\u00a0aspirin (75 mg\u00a0to 150 mg) can induce complete or near-complete inhibition of COX-1, thus inhibiting the production of TXA2, while larger doses are required to inhibit COX-2. [4]"}
{"id": "article-17708_6", "title": "Antiplatelet Medications -- Mechanism of Action", "content": "Oral thienopyridines\u00a0selectively inhibit adenosine diphosphate-induced (ADP-induced) platelet aggregation. These drugs are converted into the active drug with the help of the hepatic CYP450 system that can irreversibly inhibit the platelet P2Y12 receptor. Prasugrel is the most potent of all three drugs, has a rapid onset of action, and is superior to clopidogrel in patients undergoing coronary\u00a0stenting. Cangrelor\u00a0is a new intravenous, reversible P2Y12\u00a0receptor antagonist and has a rapid onset of action. It achieves a significant degree of platelet inhibition compared with clopidogrel. [5]", "contents": "Antiplatelet Medications -- Mechanism of Action. Oral thienopyridines\u00a0selectively inhibit adenosine diphosphate-induced (ADP-induced) platelet aggregation. These drugs are converted into the active drug with the help of the hepatic CYP450 system that can irreversibly inhibit the platelet P2Y12 receptor. Prasugrel is the most potent of all three drugs, has a rapid onset of action, and is superior to clopidogrel in patients undergoing coronary\u00a0stenting. Cangrelor\u00a0is a new intravenous, reversible P2Y12\u00a0receptor antagonist and has a rapid onset of action. It achieves a significant degree of platelet inhibition compared with clopidogrel. [5]"}
{"id": "article-17708_7", "title": "Antiplatelet Medications -- Mechanism of Action", "content": "Glycoprotein platelet inhibitors work by inhibiting glycoprotein IIb/IIIa (GpIIb-IIIa) receptors on platelets, thus decreasing platelet aggregation, and most commonly used in ACS. [3] These drugs are only available\u00a0in an intravenous form and are therefore used as short-term therapy.", "contents": "Antiplatelet Medications -- Mechanism of Action. Glycoprotein platelet inhibitors work by inhibiting glycoprotein IIb/IIIa (GpIIb-IIIa) receptors on platelets, thus decreasing platelet aggregation, and most commonly used in ACS. [3] These drugs are only available\u00a0in an intravenous form and are therefore used as short-term therapy."}
{"id": "article-17708_8", "title": "Antiplatelet Medications -- Mechanism of Action", "content": "Dipyridamole has antiplatelet and vasodilating properties and inhibits\u00a0platelet cyclic nucleotide phosphodiesterase. This enzyme is responsible\u00a0for the degradation of adenosine monophosphate (AMP) to 5'AMP, which increases intra-platelet cyclic AMP accumulation and inhibits\u00a0platelet aggregation. It also blocks the uptake of adenosine by the platelets, which also increases cyclic AMP. [6]", "contents": "Antiplatelet Medications -- Mechanism of Action. Dipyridamole has antiplatelet and vasodilating properties and inhibits\u00a0platelet cyclic nucleotide phosphodiesterase. This enzyme is responsible\u00a0for the degradation of adenosine monophosphate (AMP) to 5'AMP, which increases intra-platelet cyclic AMP accumulation and inhibits\u00a0platelet aggregation. It also blocks the uptake of adenosine by the platelets, which also increases cyclic AMP. [6]"}
{"id": "article-17708_9", "title": "Antiplatelet Medications -- Mechanism of Action", "content": "Cilostazol is also reported to have vasodilatory, antiplatelet properties, and antiproliferative effects. It also reduces smooth muscle cell hyperproliferation and intimal hyperplasia after an injury to the endothelium. [7]", "contents": "Antiplatelet Medications -- Mechanism of Action. Cilostazol is also reported to have vasodilatory, antiplatelet properties, and antiproliferative effects. It also reduces smooth muscle cell hyperproliferation and intimal hyperplasia after an injury to the endothelium. [7]"}
{"id": "article-17708_10", "title": "Antiplatelet Medications -- Administration", "content": "Antiplatelet agent administration can\u00a0be via oral, rectal, or intravenous routes. Oral medications include aspirin, clopidogrel, ticagrelor, cilostazol, and dipyridamole. Intravenous drugs include GpII-IIIA inhibitors and can be used for a short period, most commonly during acute coronary syndromes before or during PCI. Aspirin is available as a rectal suppository if the patient cannot take the drug orally. Individual agent dosing is covered under the articles for each of these drugs on the Statpearls platform. The reader is advised to seek those articles out for specific dosing information.", "contents": "Antiplatelet Medications -- Administration. Antiplatelet agent administration can\u00a0be via oral, rectal, or intravenous routes. Oral medications include aspirin, clopidogrel, ticagrelor, cilostazol, and dipyridamole. Intravenous drugs include GpII-IIIA inhibitors and can be used for a short period, most commonly during acute coronary syndromes before or during PCI. Aspirin is available as a rectal suppository if the patient cannot take the drug orally. Individual agent dosing is covered under the articles for each of these drugs on the Statpearls platform. The reader is advised to seek those articles out for specific dosing information."}
{"id": "article-17708_11", "title": "Antiplatelet Medications -- Adverse Effects", "content": "Following are the most common adverse effects associated\u00a0with antiplatelet medications: [8] Aspirin-induced asthma Nasal polyps Upper gastrointestinal bleeding because of\u00a0chronic gastritis Ecchymosis Hematuria Epistaxis Ticagrelor-related dyspnea Hemorrhage Thrombocytopenia Headache, nausea, diarrhea, pain, infection, upper respiratory symptoms, palpitations, arrhythmias, and peripheral edema are the most common side effects associated with cilostazol.", "contents": "Antiplatelet Medications -- Adverse Effects. Following are the most common adverse effects associated\u00a0with antiplatelet medications: [8] Aspirin-induced asthma Nasal polyps Upper gastrointestinal bleeding because of\u00a0chronic gastritis Ecchymosis Hematuria Epistaxis Ticagrelor-related dyspnea Hemorrhage Thrombocytopenia Headache, nausea, diarrhea, pain, infection, upper respiratory symptoms, palpitations, arrhythmias, and peripheral edema are the most common side effects associated with cilostazol."}
{"id": "article-17708_12", "title": "Antiplatelet Medications -- Contraindications", "content": "The most common\u00a0contraindications\u00a0for using antiplatelet agents are as follows [9] : Large esophageal varices Recent stroke within two years History of intracranial hemorrhage Significant thrombocytopenia Major surgery with 72 hours Hypersensitivity to the medication Acute clinically significant bleed End-stage renal disease on hemodialysis Decompensated liver cirrhosis Severe hypertension with a BP over 200/110 mmHg Congestive heart failure is a contraindication for the use of cilostazol", "contents": "Antiplatelet Medications -- Contraindications. The most common\u00a0contraindications\u00a0for using antiplatelet agents are as follows [9] : Large esophageal varices Recent stroke within two years History of intracranial hemorrhage Significant thrombocytopenia Major surgery with 72 hours Hypersensitivity to the medication Acute clinically significant bleed End-stage renal disease on hemodialysis Decompensated liver cirrhosis Severe hypertension with a BP over 200/110 mmHg Congestive heart failure is a contraindication for the use of cilostazol"}
{"id": "article-17708_13", "title": "Antiplatelet Medications -- Monitoring", "content": "Before starting antiplatelet agents, the patient should undergo an assessment for bleeding risk. Advanced age, female gender, and impaired\u00a0renal function are\u00a0important\u00a0factors to consider. The patient should be aware of the risks, benefits, and alternatives\u00a0of antiplatelet agents. Monitoring is generally not required\u00a0for antiplatelet medications; however, if bleeding is present, bleeding time will be helpful to determine if a platelet transfusion is needed or if the medication requires discontinuation. In life-threatening\u00a0bleeding such as massive upper gastrointestinal bleed, the clinician should stop the drug as soon as possible. If the antiplatelet is an essential therapy, such as in post-coronary stenting\u00a0patients, the medications should be resumed as quickly as safely possible.", "contents": "Antiplatelet Medications -- Monitoring. Before starting antiplatelet agents, the patient should undergo an assessment for bleeding risk. Advanced age, female gender, and impaired\u00a0renal function are\u00a0important\u00a0factors to consider. The patient should be aware of the risks, benefits, and alternatives\u00a0of antiplatelet agents. Monitoring is generally not required\u00a0for antiplatelet medications; however, if bleeding is present, bleeding time will be helpful to determine if a platelet transfusion is needed or if the medication requires discontinuation. In life-threatening\u00a0bleeding such as massive upper gastrointestinal bleed, the clinician should stop the drug as soon as possible. If the antiplatelet is an essential therapy, such as in post-coronary stenting\u00a0patients, the medications should be resumed as quickly as safely possible."}
{"id": "article-17708_14", "title": "Antiplatelet Medications -- Monitoring", "content": "The use of concomitant anticoagulants should be minimized as much as possible as it will increase the risk of bleeding by many times. Discontinuance of clopidogrel and ticagrelor should be at least five days and prasugrel at least seven days before major cardiac or non-cardiac surgery.", "contents": "Antiplatelet Medications -- Monitoring. The use of concomitant anticoagulants should be minimized as much as possible as it will increase the risk of bleeding by many times. Discontinuance of clopidogrel and ticagrelor should be at least five days and prasugrel at least seven days before major cardiac or non-cardiac surgery."}
{"id": "article-17708_15", "title": "Antiplatelet Medications -- Toxicity", "content": "Aspirin is the most commonly used of all antiplatelet drugs, so accidental intake is common.\u00a0The effect can be life-threatening if taken over 150 mg/kg of body weight. Supportive measure to decrease the absorption of the drug is achievable by using activated charcoal but only if administered within 4 hours of ingestion. The patient will need monitoring for signs and symptoms of bleeding and the development of metabolic derangements, such as acidosis. If acidosis develops, immediate dialysis is indicated. [10] There is no antidote available for most of these drugs; however, a monoclonal antibody\u00a0against ticagrelor is in development, but it is not commercially available as yet.", "contents": "Antiplatelet Medications -- Toxicity. Aspirin is the most commonly used of all antiplatelet drugs, so accidental intake is common.\u00a0The effect can be life-threatening if taken over 150 mg/kg of body weight. Supportive measure to decrease the absorption of the drug is achievable by using activated charcoal but only if administered within 4 hours of ingestion. The patient will need monitoring for signs and symptoms of bleeding and the development of metabolic derangements, such as acidosis. If acidosis develops, immediate dialysis is indicated. [10] There is no antidote available for most of these drugs; however, a monoclonal antibody\u00a0against ticagrelor is in development, but it is not commercially available as yet."}
{"id": "article-17708_16", "title": "Antiplatelet Medications -- Enhancing Healthcare Team Outcomes", "content": "Antiplatelet drug therapy requires an interprofessional team approach, including clinicians (MDs, DOs, NPs, PAs), specialty-trained nurses, and pharmacists. These professionals must all collaborate and engage\u00a0in open communication as an interprofessional team to achieve optimal patient results.", "contents": "Antiplatelet Medications -- Enhancing Healthcare Team Outcomes. Antiplatelet drug therapy requires an interprofessional team approach, including clinicians (MDs, DOs, NPs, PAs), specialty-trained nurses, and pharmacists. These professionals must all collaborate and engage\u00a0in open communication as an interprofessional team to achieve optimal patient results."}
{"id": "article-17708_17", "title": "Antiplatelet Medications -- Enhancing Healthcare Team Outcomes", "content": "The choice of an antiplatelet agent depends on the clinical situation. Because of the availability of a large number of antiplatelet agents, the ordering/prescribing clinician should consult with a cardiology or pharmacotherapy specialized pharmacist. When prescribing these agents, the pharmacist should review the patient's medication list as well as past diagnoses to determine if specific agents are recommended or contraindicated. Communication between the clinical provider and the pharmacists is essential to minimize adverse outcomes for patients when using these drugs. A cardiac\u00a0pharmacist can offer direction regarding agent selection, drug-drug interactions, dose verification, and overall medication reconciliation for high-risk patients.", "contents": "Antiplatelet Medications -- Enhancing Healthcare Team Outcomes. The choice of an antiplatelet agent depends on the clinical situation. Because of the availability of a large number of antiplatelet agents, the ordering/prescribing clinician should consult with a cardiology or pharmacotherapy specialized pharmacist. When prescribing these agents, the pharmacist should review the patient's medication list as well as past diagnoses to determine if specific agents are recommended or contraindicated. Communication between the clinical provider and the pharmacists is essential to minimize adverse outcomes for patients when using these drugs. A cardiac\u00a0pharmacist can offer direction regarding agent selection, drug-drug interactions, dose verification, and overall medication reconciliation for high-risk patients."}
{"id": "article-17708_18", "title": "Antiplatelet Medications -- Enhancing Healthcare Team Outcomes", "content": "The role of the cardiac nurse administering these medications in the acute setting involves monitoring for any acute adverse symptoms and patient education in regards to the same. Prompt communication by the astute nursing staff of an adverse reaction or a complication can significantly reduce patient morbidity and mortality.", "contents": "Antiplatelet Medications -- Enhancing Healthcare Team Outcomes. The role of the cardiac nurse administering these medications in the acute setting involves monitoring for any acute adverse symptoms and patient education in regards to the same. Prompt communication by the astute nursing staff of an adverse reaction or a complication can significantly reduce patient morbidity and mortality."}
{"id": "article-17708_19", "title": "Antiplatelet Medications -- Enhancing Healthcare Team Outcomes", "content": "Nurses are often the first healthcare provider to verify the therapeutic effectiveness of these agents and to monitor for adverse effects. This role becomes crucial in patients receiving dual antiplatelet therapy, as is often the case for\u00a0the prevention\u00a0of stent thrombosis or after an ACS event. The specialty-trained nurse not only educates the patient on possible complications but also regarding the indications for the prescribed therapy as well as the need for adherence to the medication treatment regimen. The nurse should communicate with the clinical provider and the pharmacist if noting any adverse reaction or if there is a concern for patient adherence with drug therapy so that alternative therapies can be considered. An interprofessional approach, with a multifaceted and targetted approach to treatment, is necessary to improve patient outcomes with antiplatelet medications.\u00a0[Level 5]", "contents": "Antiplatelet Medications -- Enhancing Healthcare Team Outcomes. Nurses are often the first healthcare provider to verify the therapeutic effectiveness of these agents and to monitor for adverse effects. This role becomes crucial in patients receiving dual antiplatelet therapy, as is often the case for\u00a0the prevention\u00a0of stent thrombosis or after an ACS event. The specialty-trained nurse not only educates the patient on possible complications but also regarding the indications for the prescribed therapy as well as the need for adherence to the medication treatment regimen. The nurse should communicate with the clinical provider and the pharmacist if noting any adverse reaction or if there is a concern for patient adherence with drug therapy so that alternative therapies can be considered. An interprofessional approach, with a multifaceted and targetted approach to treatment, is necessary to improve patient outcomes with antiplatelet medications.\u00a0[Level 5]"}
{"id": "article-17708_20", "title": "Antiplatelet Medications -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Antiplatelet Medications -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}